ArticleAIDS and behavior2026
Trends in HCV Prevalence and Risk Factors Among People who Inject Drugs in Los Angeles County, 2012-2024.
Article in AIDS and behavior, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Evaluating trends in Hepatitis C virus (HCV) prevalence is critical for tracking the progress in HCV elimination efforts. We evaluated the changes in the prevalence of HCV infection (HCV antibody) among people who inject drugs (PWID) participating in the National HIV Behavioral Surveillance in Los Angeles County (LAC). Steady decreases in HCV antibody seroprevalence over time was observed among PWID from 81.2% in 2012 to 64.9% in 2015, 59.1% in 2018, 50.1% in 2022, and 34.2% in 2024. Chronic HCV infection (positive on both antibody and RNA tests) also declined from 37.1% in 2018 to 30.6% in 2022 and 18.2% in 2024. This downward pattern is further supported by multivariable analyses which showed a consistent reduction in HCV prevalence over time (aPR = 0.91, 95% CI 0.89-0.92). The largest decreases occurred among participants aged ≥ 30 years and among female PWID, with both decreasing 9.1% annually. HCV antibody positivity remained significantly higher among males, those with lower education, daily injectors, participants with incarceration history, and those engaging in receptive syringe sharing. Decreases in HCV antibody and RNA prevalence, alongside improved sterile injection practices, greater awareness of HCV status, and increases in treatment uptake, may reflect the impact of harm reduction efforts at reducing transmission among PWID in LAC. To achieve and sustain equitable progress, it remains essential to continue expanding HCV testing and treatment, particularly for communities that have not yet fully benefited from these interventions.
Indexed as
Identifiers
41746467What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.